ORGANON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Organon & Co. and Encourages Investors to Contact the FirmNEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (
NYSE:OGN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Organon securities between October 31, 2024, to April 30, 2025, both dates inclusive (the “Class Period”). Investors have until July 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Law Offices of Howard G. Smith Encourages Organon & Co. (OGN) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Organon & Co. (“Organon” or the “Company”) (
NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). Organon investors have until July 22, 2025 to file a lead plaintiff motion.
CLASS ACTION NOTICE: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class ActionPHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (
NYSE: OGN) on behalf of purchasers of Organon securities between October 31, 2024 through April 30, 2025, inclusive (the “Class Period”).
Securities Fraud Investigation Into Organon & Co. (OGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (
NYSE: OGN) investors concerning the Company’s possible violations of the federal securities laws.
Organon & Co. (OGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (
NYSE: OGN) investors concerning the Company’s possible violations of federal securities laws.
OGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (
NYSE: OGN) securities and charges Organon and certain of Organon’s executives with violations of the Securities Exchange Act of 1934.
ORGANON BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNNEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (
NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Securities Fraud Investigation Into Organon & Co. (OGN) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Organon & Co. (“Organon” or the “Company”) (
NYSE: OGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Rosen Law Firm Urges Organon & Co. (NYSE: OGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Organon & Co. (
NYSE: OGN) securities between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”). Organon is a healthcare company.
OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
OGN BREAKING NEWS: Organon & Co. Stock Plummets 27% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NYSE:OGN)
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (
NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNNEW YORK and NEW ORLEANS, May 27, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (
NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Rosen Law Firm Encourages Organon & Co. Investors to Inquire About Securities Class Action Investigation – OGN
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Organon & Co. (
NYSE: OGN) resulting from allegations that Organon may have issued materially misleading business information to the investing public.
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To KnowA number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025.
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Samsung Bioepis Co., Ltd. and Organon & Co. (
NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira® (adalimumab).2 These interchangeability designations follow the interchangeability designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024.1 With today’s additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the reference product.1,2 An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, depending on state pharmacy laws.4
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. (“Organon” or “the Company”) (
NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ORGANON SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (
NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
OGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (
NYSE: OGN) securities and charges Organon as well as certain of Organon’s executives with violations of the Securities Exchange Act of 1934.
3 Low-Volatility Stocks with Questionable FundamentalsLow-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the FirmNEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims Organon & Co. (
NYSE:OGN), Landstar System, Inc. (
NASDAQ:LSTR), Arvinas, Inc. (
NASDAQ:ARVN), and GoHealth, Inc. (
NASDAQ:GOCO). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
OGN Q1 Earnings Call: Revenue Exceeds Expectations Amid Strategic Focus on Deleveraging and Product GrowthPharmaceutical company Organon (
NYSE:OGN) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share was 14.2% above analysts’ consensus estimates.
